Pseudomonas aeruginosa (P.a.) are resistant to most antibiotics and cause life-threatening infections of wounds or the lungs. The P.a. bacteria species has an entire arsenal of strategies for evading the immune system and infecting tissue. Researchers working with Prof. Dr. Winfried Romer an
Scientists have unearthed a secret that may explain why some people are able to resist viral infections, having screened the immune systems of women exposed to hepatitis C (HCV) through contaminated anti-D transfusions given over 40 years ago in Ireland.
Scientists from Trinity College Dublin have unearthed a secret that may explain why some people are able to resist viral infections, having screened the immune systems of women exposed to hepatitis C (HCV) through contaminated anti-D transfusions given over 40 years ago in Ireland.
The diverse functions of immune cells in the body are extremely rigorously controlled in order to combat infections. How Toxoplasma infects so many people and animal species and spreads so quickly has long been a mystery to scientists.
A new drug combination has been found to be more effective, especially against persistent, drug-resistant infections, according to an international study led by a Rutgers scientist comparing new and older treatments for complicated urinary tract infections.
A combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation than a standard treatment combining piperacillin and tazobactam.
Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new research.
A combination of the drugs cefepime and enmetazobactam was more effective in treating both complicated urinary tract infections and acute pyelonephritis (AP), a bacterial infection causing kidney inflammation, than a standard treatment combining piperacillin and tazobactam.
An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.